Anaptysbio (ANAB) Shares Outstanding (Weighted Average) (2016 - 2026)
Anaptysbio posted quarterly Shares Outstanding (Weighted Average) of $28.7 million for Q1 2026, down 6.37% year-on-year from $30.6 million in Q1 2025, and little changed on a QoQ basis from $28.8 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $28.7 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 6.37% year-over-year to $28.7 million; the trailing twelve-month figure through Mar 2026 stood at $28.7 million (down 6.37% YoY), and the FY2025 full-year result was $28.8 million, up 1.32% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $28.7 million, roughly flat from $28.8 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $30.6 million in Q1 2025 and bottomed at $26.8 million in Q1 2024.
- The 5-year median for Shares Outstanding (Weighted Average) is $28.0 million (2023), against an average of $28.0 million.
- The widest annual swing landed in 2025, when Shares Outstanding (Weighted Average) increased 14.34%; it then fell 6.37% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $28.2 million in 2022, then decreased by 4.41% to $26.9 million in 2023, then climbed by 5.42% to $28.4 million in 2024, then grew by 1.32% to $28.8 million in 2025, then slipped by 0.23% to $28.7 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $28.7 million (Q1 2026), $28.8 million (Q4 2025), and $27.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | 28.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.69 Mn |
| Dec 31, 2025 | 28.76 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 28.81 Mn |
| Mar 31, 2025 | 30.64 Mn |
| Dec 31, 2024 | 28.38 Mn |
| Sep 30, 2024 | 27.69 Mn |
| Jun 30, 2024 | 27.08 Mn |
| Mar 31, 2024 | 26.80 Mn |
| Dec 31, 2023 | 26.92 Mn |
| Sep 30, 2023 | 27.04 Mn |
| Jun 30, 2023 | 27.29 Mn |
| Mar 31, 2023 | 27.95 Mn |
| Dec 31, 2022 | 28.17 Mn |
| Sep 30, 2022 | 28.07 Mn |
| Jun 30, 2022 | 27.96 Mn |
| Mar 31, 2022 | 27.71 Mn |
| Dec 31, 2021 | 27.43 Mn |
| Sep 30, 2021 | 27.40 Mn |
| Jun 30, 2021 | 27.38 Mn |
| Mar 31, 2021 | 27.36 Mn |
| Dec 31, 2020 | 27.30 Mn |
| Sep 30, 2020 | 27.29 Mn |
| Jun 30, 2020 | 27.28 Mn |
| Mar 31, 2020 | 27.26 Mn |
| Dec 31, 2019 | 27.06 Mn |
| Sep 30, 2019 | 27.02 Mn |
| Jun 30, 2019 | 27.03 Mn |
| Mar 31, 2019 | 26.98 Mn |
| Dec 31, 2018 | 24.67 Mn |
| Sep 30, 2018 | 24.15 Mn |
| Jun 30, 2018 | 23.93 Mn |
| Mar 31, 2018 | 23.80 Mn |
| Dec 31, 2017 | 19.78 Mn |
| Sep 30, 2017 | 18.67 Mn |
| Jun 30, 2017 | 20.27 Mn |
| Mar 31, 2017 | 15.30 Mn |
| Dec 31, 2016 | 2.64 Mn |
| Sep 30, 2016 | 2.64 Mn |
| Jun 30, 2016 | 2.64 Mn |
| Mar 31, 2016 | 2.63 Mn |